Every material Form 8-K Acurx Pharmaceuticals, Inc. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acurx Pharmaceuticals filed a certificate of amendment to combine every twenty shares of its common stock into one share, effective 4:01 p.m. Eastern Time on August 4, 2025. The company says the split is intended to raise the per-share trading price so it can regain compliance with Nasdaq's minimum bid price requirement. Shareholders will receive cash in lieu of any fractional shares, and the number of authorized shares will not change.
Ratio is 1-for-20, with shares expected to trade on a split-adjusted basis on The Nasdaq Capital Market from August 5, 2025 under the symbol ACXP
Shares outstanding are expected to fall from about 30,764,540 as of July 24, 2025 to about 1,538,227 after the split
Stockholders approved the reverse split at the annual meeting held July 17, 2025
The stated purpose is to help the company regain compliance with Nasdaq's minimum bid price requirement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acurx Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →